# A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors

> **NCT01068977** · PHASE1 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 44 (actual)

## Conditions studied

- Solid Cancers

## Interventions

- **DRUG:** bevacizumab
- **DRUG:** MetMAb
- **DRUG:** MetMAb

## Key facts

- **NCT ID:** NCT01068977
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2017-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01068977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01068977, "A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01068977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*